These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24626184)

  • 1. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
    Iyer RS; Nicol SM; Quinlan PR; Thompson AM; Meek DW; Fuller-Pace FV
    Cell Cycle; 2014; 13(9):1413-23. PubMed ID: 24626184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.
    King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW
    Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer.
    Moore HC; Jordan LB; Bray SE; Baker L; Quinlan PR; Purdie CA; Thompson AM; Bourdon JC; Fuller-Pace FV
    Oncogene; 2010 Dec; 29(49):6475-84. PubMed ID: 20818423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53-dependent repression of polo-like kinase-1 (PLK1).
    McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
    Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
    Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
    Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the RNA helicase p68 (Ddx5) as a transcriptional regulator.
    Nicol SM; Fuller-Pace FV
    Methods Mol Biol; 2010; 587():265-79. PubMed ID: 20225156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of
    Zhang J; Wang Y; Shen Y; He P; Ding J; Chen Y
    Theranostics; 2018; 8(10):2884-2895. PubMed ID: 29774081
    [No Abstract]   [Full Text] [Related]  

  • 9. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
    Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
    Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
    [TBL] [Abstract][Full Text] [Related]  

  • 10.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1).
    Chang YC; Wu CH; Yen TC; Ouyang P
    J Biol Chem; 2012 Feb; 287(6):4376-85. PubMed ID: 22184120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular interactions of polo-like kinase 1 in human cancers.
    Weng Ng WT; Shin JS; Roberts TL; Wang B; Lee CS
    J Clin Pathol; 2016 Jul; 69(7):557-62. PubMed ID: 26941182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.
    Louwen F; Yuan J
    Oncotarget; 2013 Jul; 4(7):958-71. PubMed ID: 23948487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of p68 RNA Helicase (DDX5) Activates a Survival Pathway Involving mTOR and MDM2 Signals.
    Kokolo M; Bach-Elias M
    Folia Biol (Praha); 2017; 63(2):52-59. PubMed ID: 28557706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
    Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
    Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer.
    Hashemi V; Masjedi A; Hazhir-Karzar B; Tanomand A; Shotorbani SS; Hojjat-Farsangi M; Ghalamfarsa G; Azizi G; Anvari E; Baradaran B; Jadidi-Niaragh F
    J Cell Physiol; 2019 May; 234(5):5478-5487. PubMed ID: 30417346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M; Quaas M; Nickel A; Engeland K
    Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage.
    Nicol SM; Bray SE; Black HD; Lorimore SA; Wright EG; Lane DP; Meek DW; Coates PJ; Fuller-Pace FV
    Oncogene; 2013 Jul; 32(29):3461-9. PubMed ID: 22986526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.